Gilead Sciences Inc
NASDAQ: GILD
$92.58
+$0.17 (+0.2%)
Closing Price on November 29, 2024
GILD Articles
Gilead Sciences is going to raise cash via a huge debt offering. Will this cash be used to fund a large buyout? Will it be used for stock and/or debt buybacks?
Published:
The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
24/7 Wall St. has wanted to check on the major stocks in the market with an eagle-eye view of where investors may start to buy stocks, as long as they do not feel this is the start of the next global...
Published:
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
Published:
ThinkstockMost analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part the resulting...
Published:
Last Updated:
Jon OggStocks were indicated higher on Wednesday ahead of the pending FOMC decision on interest rates. Tuesday’s rally was yet another instance where investors proved that they want to buy stocks...
Published:
courtesy of Gilead SciencesGilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on...
Published:
Last Updated:
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break...
Published:
Last Updated:
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc....
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Alarm.com, Pandora Media, PayPal, SanDisk, SunEdison, Tesla Motors and Advanced Micro Devices.
Published:
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Published:
Merrill Lynch recently updated its view on Gilead Sciences, maintaining its Underperform rating for the stock but raising its price objective
Published:
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Published:
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Published: